IP Library Patent Application 17834798
Patent Application
App. No. 17/834,798

MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/834,798
Abstract

Synthetic cannabinoid medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The synthetic cannabinoid composition/carrier combinations can create administration benefits.

Claims (38)

1 .- 37 . (canceled)

38 . A method of providing increased bioavailability within a subject of a synthetic cannabinoid with an aqueous solubility of less than 0.1 mg/ml, the method comprising:

administering an effective amount of a solution to the subject, wherein the solution consists of:

aqueous ethanol;

the synthetic cannabinoid with the aqueous solubility of less than 0.1 mg/ml; and

an N-acylated fatty amino acid or a salt thereof comprising the formula:

wherein X and Z are independently hydrogen, a monovalent cation, a divalent metal cation, or an organic cation,

thereby providing the increased bioavailability of the synthetic cannabinoid within the subject, when compared to the same solution without the added N-acylated fatty amino acid.

39 . The method of claim 38 , wherein the synthetic cannabinoid comprises nabilone.

40 . A solution consisting of:

aqueous ethanol;

a synthetic cannabinoid or a salt thereof having a water solubility of less than 0.1 mg/ml; and

an N-acylated fatty amino acid or a salt thereof having the formula:

wherein X and Z are independently hydrogen, a monovalent cation, a divalent metal cation, or an organic cation, and

wherein the solution increases bioavailability of the synthetic cannabinoid or the salt thereof following administration to a subject as compared to the solution consisting of the synthetic cannabinoid or the salt thereof but lacking the N-acylated fatty amino acid or the salt thereof.

41 . The composition of claim 40 , wherein the N-acylated fatty amino acid or the salt thereof is N-[8-(2-hydroxybenzoyl) amino] caprylate.

42 . The composition of claim 41 , wherein the composition comprises 100-200 mg N-[8-(2-hydroxybenzoyl) amino] caprylate.

43 . The composition of claim 40 , further comprising:

at least one of a flavonoid compound, a terpene, or a terpenoid.

44 . The composition of claim 40 , wherein X is hydrogen, sodium, potassium, calcium, magnesium, ammonium or tetramethylammonium.

45 . The composition of claim 40 , wherein Z is hydrogen, sodium, potassium, calcium or magnesium.

46 . The composition of claim 40 , wherein X is hydrogen and Z is hydrogen.

47 . The composition of claim 40 , wherein X is hydrogen and Z is sodium.

48 . The composition of claim 40 , wherein X is sodium and Z is sodium.

49 . The composition of claim 40 , wherein the N-acylated fatty amino acid or the salt thereof and the synthetic cannabinoid or the salt thereof are present at a weight ratio of between 1:1 and 100:1.

50 . The composition of claim 40 , wherein the synthetic cannabinoid or the salt thereof is nabilone.

51 . A composition formulated for oral delivery, the composition comprising:

aqueous ethanol;

a synthetic cannabinoid or a salt thereof having a water solubility of less than 0.1 mg/ml; and

an absorption enhancer consisting of an N-acylated fatty amino acid or a salt thereof having the formula:

wherein X and Z are independently hydrogen, a monovalent cation, a divalent metal cation, or an organic cation; and

one or more excipients dispersing agents and/or suspending agents.

52 . The composition of claim 51 , wherein the N-acylated fatty amino acid or the salt thereof is N-[8-(2-hydroxybenzoyl) amino] caprylate.

53 . The composition of claim 52 , wherein the amount of the absorption enhancer is 100-200 mg N-[8-(2-hydroxybenzoyl) amino] caprylate.

54 . The composition of claim 51 , wherein X is hydrogen, sodium, potassium, calcium, magnesium, ammonium or tetramethylammonium.

55 . The composition of claim 51 , wherein Z is hydrogen, sodium, potassium, calcium or magnesium.

56 . The composition of claim 51 , wherein the N-acylated fatty amino acid or the salt thereof and the synthetic cannabinoid or the salt thereof are present at a weight ratio of between 1:1 and 100:1.

57 . The composition of claim 51 , wherein the synthetic cannabinoid or the salt thereof is nabilone.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2024
From: LEONE-BAY, ANDREA; WESNER, GREGORY
To: RECEPTOR LIFE SCIENCES, INC.
Reel/Frame 066039/0148 →
CHANGE OF NAME Recorded Jan 5, 2024
From: RECEPTOR LIFE SCIENCES, INC.
To: RECEPTOR HOLDINGS, INC.
Reel/Frame 066208/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2023
From: RECEPTOR HOLDINGS INC.
To: SPOKE SCIENCES, INC
Reel/Frame 065427/0133 →